GlassScriptPhysician profile
Seema B Sood
NPI 1386669117
$1,583.94
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $437 · 2021: $173 · 2022: $92.59 · 2023: $201 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $273.59 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $225.98 | 2019-2021 | |
| Abbott Laboratories | $210.00 | 2019-2020 | |
| Amarin Pharma, INC. | $163.95 | 2019 | |
| Abbvie INC. | $133.87 | 2019-2023 | Rinvoq |
| Astrazeneca Pharmaceuticals LP | $111.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $100.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $49.54 | 2022-2023 | |
| Novo Nordisk INC | $39.46 | 2023-2024 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $38.03 | 2020 | |
| Lilly USA, LLC | $29.29 | 2020 | |
| Allergan, INC. | $27.95 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $27.65 | 2023 | Givlaari |
| Phathom Pharmaceuticals, INC. | $24.39 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $24.29 | 2023 | Shingrix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $18.34 | 2023 | |
| Medtronic USA, INC. | $17.75 | 2019 | |
| Bardy Diagnostics, INC. | $16.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.97 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.53 | 2019 | |
| Ethicon US, LLC | $12.07 | 2020 | |
| Shire North American Group INC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.